

REF



SYSTEM

07028172119

07028172500

100

cobas e 801

English

System information

Short name	ACN (application code number)
GDF-15	10127

Intended use

Immunoassay for the in vitro quantitative determination of Growth Differentiation Factor-15 (GDF-15) in human serum and plasma.

The Elecsys GDF-15 assay is intended as an aid in risk stratification of patients with Non-ST Elevation (NSTEMI) Acute Coronary Syndrome (ACS) or Chronic Heart Failure (CHF). The Elecsys GDF-15 assay is intended as an aid in risk prediction of major bleeding events of patients with Atrial Fibrillation (AF).

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the **cobas e 801** immunoassay analyzer.

Note: Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit Catalogue Number: 07028172190 for the Elecsys GDF-15 assay. The last 3 digits

-190 have been replaced by -119 for logistic purposes.

Summary

GDF-15 is a member of the transforming growth factor β (TGF- β) cytokine superfamily.

GDF-15 levels increase sharply in response to pathological or physiological stress associated with inflammation, hypoxia, tissue injury and remodelling as observed in cardiovascular diseases, as well as in some tumors and pregnancy.^{1,2} Levels of GDF-15 increase with the severity of cardiovascular diseases: elevated serum levels are found in stable coronary artery disease, ACS and heart failure (HF).²

Increasing evidence indicates that GDF-15 levels predict adverse outcomes of cardiovascular disease, independently from traditional risk factors such as previous myocardial infarction (MI), age, elevated levels of cardiac troponin T, N-terminal pro B-type natriuretic peptide, or high-sensitivity C-reactive protein. Increased GDF-15 levels are indicative of high mortality in patients with ST-segment elevation ACS (STE-ACS),³ non-ST-elevation ACS (NSTEMI-ACS)^{4,5,6} and HF.^{7,8} Higher levels of GDF-15 also identify NSTEMI-ACS patients at an elevated risk of recurrent MI⁴ and bleeding.⁶

Adding GDF-15 levels to the Global Registry of Acute Coronary Events (GRACE) score further improves the prediction of 6-month all-cause mortality and non-fatal MI in patients with NSTEMI-ACS.⁹ High levels of GDF-15 are also associated with increased risk of developing HF following an episode of ACS.¹⁰ Therefore GDF-15 levels potentially allow identifying which ACS patients will benefit from more aggressive therapies aimed at reducing HF-related admissions.

AF is highly associated with major risk for stroke and death. The development and risk of stroke can be mitigated by control of risk factors and oral anticoagulation therapy. However, anticoagulant therapy is strongly associated with a risk of major bleeding. Clinical practice points to the benefit of oral anticoagulation in AF on a balance between reduction in ischemic stroke and increase in major bleeding events. In clinical practice the risk of bleeding can be assessed by e.g. the HAS-BLED¹¹ score and more recently by the ORBIT¹² score, which are based on clinical risk factors only. However, several new biomarkers have now been shown to provide incremental information about the risk of bleeding in AF patients. The recently introduced risk modelling score termed "ABC-bleeding risk score" taking into account age, biomarkers (GDF-15, cTNT-hs, and hemoglobin) and clinical history was shown to significantly improve the prediction of bleeding events of AF patients.¹³ The ABC-bleeding risk score could therefore be a valuable decision support tool regarding indications for and selection of treatment with oral anticoagulants in patients with AF.

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: Antigen in the sample (21 μ L), a biotinylated monoclonal GDF-15-specific antibody, and a monoclonal GDF-15-specific antibody labeled with a ruthenium complex^{a)} form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas link**.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The **cobas e** pack is labeled as GDF-15.

- M Streptavidin-coated microparticles, 1 bottle, 6.1 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-GDF-15-Ab~biotin, 1 bottle, 7.6 mL: Biotinylated monoclonal anti-GDF-15 antibody (mouse) 1.5 μ g/mL; phosphate buffer 95 mmol/L, pH 6.0; preservative.
- R2 Anti-GDF-15-Ab~Ru(bpy)₃²⁺, 1 bottle, 7.6 mL: Monoclonal anti-GDF-15 antibody (mouse) labeled with ruthenium complex 2.0 μ g/mL; phosphate buffer 95 mmol/L, pH 6.0; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

H319 Causes serious eye irritation.

Prevention:

P264 Wash skin thoroughly after handling.

P280 Wear eye protection/ face protection.

Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337 + P313 If eye irritation persists: Get medical advice/attention.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas link**.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Elecsys GDF-15



Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the cobas e 801 analyzer	16 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K₂-EDTA and K₃-EDTA plasma.

Li-heparin and K₂-EDTA plasma tubes containing separating gel can be used.

Criterion: Slope 0.9-1.1 + intercept $\leq \pm 160$ pg/mL + coefficient of correlation ≥ 0.95 .

Stable for 8 days at 20-25 °C, 14 days at 2-8 °C, 12 months at -20 °C (± 5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- REF 07125941190, CalSet GDF-15, for 4 x 1.0 mL
- REF 04917049190, PreciControl Cardiac II, for 4 x 2.0 mL
- REF 07299010190, Diluent MultiAssay, 45.2 mL sample diluent
- General laboratory equipment
- cobas e** 801 analyzer

Accessories for the **cobas e** 801 analyzer:

- REF 06908799190, ProCell II M, 2 x 2 L system solution
- REF 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- REF 07485409001, Reservoir Cups, 8 cups to supply ProCell II M and CleanCell M
- REF 06908853190, PreClean II M, 2 x 2 L wash solution
- REF 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- REF 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- REF 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- REF 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

Calibration

Traceability: This method has been standardized by weighing recombinant GDF-15 into equine serum.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Cardiac II.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample in pg/mL.

Interpretation of the results

With increasing age atherosclerosis and aging processes of the heart (e.g. fibrosis) result in cardiac dysfunction. Development of cardiac dysfunction clinically differs in individuals and is often asymptomatic in early stages.^{14,15,16} Cardiovascular (CV) disease is a major driver of increased circulating levels of GDF-15. In community-dwelling individuals, higher concentrations of GDF-15 are associated with increased risks of developing CV disease, chronic kidney disease, and certain types of cancer.^{17,18,19,20,21} GDF-15 is a marker of all-cause mortality, CV mortality, and nonfatal CV events in patients with coronary artery disease, heart failure, and atrial fibrillation.

GDF-15 levels need to be interpreted in conjunction with the medical history, clinical findings and other information (e.g. imaging, laboratory findings, accompanying disorders, treatment effects).

Based on the current results, GDF-15 in the context of the ABC-bleeding risk score might improve the prediction of major bleeding.¹³ GDF-15 as a part of the ABC-bleeding risk score is recommended with Class IIa, LOE B in the 2016 ESC AF guidelines.²²

Detailed instructions on how to calculate the patient's 1-year bleeding risk using GDF-15 results and the ABC-bleeding risk score can be found in the publication by Hijazi et al.¹³

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 1129 μ mol/L or ≤ 66 mg/dL
Hemoglobin	≤ 0.621 mmol/L or ≤ 1000 mg/dL
Intralipid	≤ 2000 mg/dL
Biotin	≤ 205 nmol/L or ≤ 50 ng/mL
Rheumatoid factors	≤ 1200 IU/mL

Elecsys GDF-15



Compound	Concentration tested
IgG	≤ 55 g/L
IgM	≤ 10 g/L
IgA	≤ 13 g/L
Albumin	≤ 70 g/L

Criterion: Recovery within ± 80 pg/mL for GDF-15 concentrations ≤ 800 pg/mL or ± 10 % for concentrations > 800-2000 pg/mL or ± 14 % for concentrations > 2000 pg/mL of initial value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

There is no high-dose hook effect at GDF-15 concentrations up to 150000 pg/mL.

Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In addition, the following special cardiac drugs were tested. No interference with the assay was found.

Special cardiac drugs

Drug	Concentration tested mg/L
Carvedilol	37.5
Clopidogrel	75.0
Digoxin	0.25
Epinephrine (adrenaline)	0.50
Insulin	1.60
Lidocaine	80.0
Lisinopril	10.0
Methylprednisolone	7.50
Metoprolol	150
Nifedipine	30.0
Phenprocoumon	3.00
Propafenone	300
Retepase	33.3
Simvastatin	30.0
Spironolactone	75.0
Tolbutamide	1500
Torasemide	15.0
Verapamil	240

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

400-20000 pg/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as < 400 pg/mL. Values above the measuring range are reported as > 20000 pg/mL (or up to 100000 pg/mL for 5-fold diluted samples).

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 350 pg/mL

Limit of Detection = 400 pg/mL

Limit of Quantitation = 400 pg/mL

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %.

Dilution

Samples with GDF-15 concentrations above the measuring range can be diluted with Diluent MultiAssay. The recommended dilution is 1:5 (either automatically by the analyzer or manually). The concentration of the diluted sample must be ≥ 3500 pg/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzer, the software automatically takes the dilution into account when calculating the sample concentration.

Expected values

Circulating levels of GDF-15 were determined in 739 samples from apparently healthy volunteers. The subjects were clinically well characterized and between 20 and 79 years old. Male and female gender was distributed equally and no difference was observed.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

The descriptive statistics for GDF-15 concentrations in the reference group are summarized in the following table:

Age years	N	Mean pg/mL	SD pg/mL	Median pg/mL	95 th percentile pg/mL
20-< 30	127	514	273	429	831
30-< 40	120	564	223	500	852
40-< 50	125	660	266	614	1229
50-< 60	119	807	285	757	1466
60-< 70	122	937	306	866	1476
≥ 70	126	1187	547	1060	2199

GDF-15 levels in cardiovascular diseases

The GDF-15 measurements reported in the three clinical performance studies described in this section were performed on the cobas e 601 analyzer.

GDF-15 derived risk stratification for CHF patients

A clinical performance study, based on samples from the HF ACTION sub study²³ was designed to evaluate GDF-15 as a risk predictor for HF and to compare its performance to established risk predictors. The primary endpoint was all-cause mortality. The secondary endpoints were cardiovascular (CV) death and heart failure (HF) hospitalization. Hierarchical Cox proportional hazards models were created where covariates were successively added for each of the endpoints. The following covariates were used: Demographics (Dem): age, sex, race, BMI (body mass index) and smoking status; Clinical parameters (Clin): etiology, NYHA class ≥ 3, left ventricular ejection fraction, aldosterone antagonist, ACEi/ARB (angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker), loop diuretic, beta blocker, hypertension, diabetes, heart rate, sodium, and glomerular filtration rate (GFR); Biomarkers: NT-proBNP, hsTnT. In total, 910 patients were included in the analysis and followed-up for 4 years.

Correlation of GDF-15 levels with NYHA classification in patients diagnosed with CHF

Increasing GDF-15 levels (pg/mL) correlate with higher NYHA classification:

	NYHA functional class		
	NYHA II	NYHA III	NYHA IV
N* (%)	569 (62.5)	329 (36.2)	12 (1.3)
Mean (pg/mL)	1958	2712	5619

	NYHA functional class		
	NYHA II	NYHA III	NYHA IV
SD (pg/mL)	2000	2503	5559
Median (pg/mL)	1425	1985	3231
5 th percentile (pg/mL)	527	615	648
95 th percentile (pg/mL)	5151	6956	≥ 20000

*Total number (N) of the sub study population n = 910. No NYHA I patient present.

Relationship of log₂-transformed GDF-15 levels with all-cause mortality alone and with the addition of covariates
 GDF-15 independently contributes to risk prediction of all-cause mortality in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	1.96 (1.70, 2.26)	< 0.0001	0.718 (0.672, 0.763)
GDF-15 + Dem	1.87 (1.58, 2.21)	< 0.0001	0.725 (0.679, 0.771)
GDF-15 + Dem + Clin	1.69 (1.39, 2.07)	< 0.0001	0.743 (0.700, 0.787)
GDF-15 + Dem + Clin + NT-proBNP	1.38 (1.11, 1.72)	0.0042	0.769 (0.728, 0.810)
GDF-15 + Dem + Clin + hsTnT	1.55 (1.25, 1.92)	< 0.0001	0.752 (0.709, 0.795)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.34 (1.07, 1.69)	0.0120	0.771 (0.729, 0.812)

*CI = confidence interval

Relationship of log₂-transformed GDF-15 levels with CV death alone and with the addition of covariates
 GDF-15 independently contributes to risk prediction of CV death in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	2.10 (1.77, 2.48)	< 0.0001	0.731 (0.677, 0.785)
GDF-15 + Dem	2.01 (1.64, 2.46)	< 0.0001	0.747 (0.693, 0.801)
GDF-15 + Dem + Clin	1.84 (1.44, 2.34)	< 0.0001	0.787 (0.741, 0.834)
GDF-15 + Dem + Clin + NT-proBNP	1.48 (1.14, 1.94)	0.0038	0.810 (0.766, 0.854)
GDF-15 + Dem + Clin + hsTnT	1.71 (1.32, 2.21)	< 0.0001	0.793 (0.747, 0.838)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.47 (1.12, 1.95)	0.0063	0.810 (0.766, 0.854)


Relationship of log₂-transformed GDF-15 levels with HF hospitalization alone and with the addition of covariates
 GDF-15 independently contributes to risk prediction of HF hospitalization in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	1.59 (1.41, 1.80)	< 0.0001	0.639 (0.599, 0.680)
GDF-15 + Dem	1.69 (1.47, 1.94)	< 0.0001	0.688 (0.653, 0.723)
GDF-15 + Dem + Clin	1.50 (1.26, 1.79)	< 0.0001	0.725 (0.690, 0.759)
GDF-15 + Dem + Clin + NT-proBNP	1.23 (1.02, 1.48)	0.0341	0.756 (0.725, 0.787)
GDF-15 + Dem + Clin + hsTnT	1.40 (1.17, 1.68)	0.0003	0.734 (0.700, 0.768)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.20 (0.99, 1.46)	0.0591	0.758 (0.727, 0.789)

These results demonstrate that GDF-15 provides significant independent prognostic information in patients with HF for the period of 4 years.

Similar models were created with categorized GDF-15 levels to define cutoffs separating patient groups with high, intermediate, and low risk for all-cause mortality and CV death as well as HF hospitalization. Creating two binary GDF-15 factors using the rounded tertiles 1200 pg/mL and 2300 pg/mL as cutoffs, i.e. comparing low versus intermediate/high GDF-15 levels and low/intermediate versus high GDF-15 levels, in two separate models, resulted in HRs of 3.10 (≥ 1200 pg/mL) and 3.40 (≥ 2300 pg/mL) for **all-cause mortality**, for **CV death** HRs were 3.55 (≥ 1200 pg/mL) and 3.81 (≥ 2300 pg/mL) and for **HF hospitalization** HRs were 2.06 (≥ 1200 pg/mL) and 2.50 (≥ 2300 pg/mL).

A similar model with a three category GDF-15 (low, intermediate and high) factor for **all-cause mortality** (see plot A below) resulted in HRs of 1.81 (intermediate vs. low) and 4.72 (high vs. low), for **CV death** (see plot B below) the HRs were 1.95 (intermediate vs. low) and 5.55 (high vs. low), and for **HF hospitalization** (see plot C below) the HRs were 1.38 (intermediate vs. low) and 2.94 (high vs. low).



Elecsys GDF-15



x = days
 y = (A) % free from all-cause mortality
 (B) % free from CV death
 (C) % free from HF hospitalization

————: < 1200 pg/mL
 — — —: 1200-2299 pg/mL
 - - -: ≥ 2300 pg/mL

GDF-15 derived risk stratification for patients with Non-ST Elevation (NSTEMI) Acute Coronary Syndrome (ACS)

A clinical performance study using samples from a biomarker sub study of the MERLIN TIMI 36²⁴ trial in NSTEMI-ACS patients was designed to evaluate GDF-15 as a risk predictor of ACS and to compare its performance to established risk predictors. The primary endpoint was all-cause mortality and the secondary endpoints were cardiovascular (CV) death and the composite of CV death/myocardial infarction (MI). Hierarchical Cox proportional hazards models were created where covariates were successively added for each of the endpoints. The following covariates were used: Demographics (Dem): age, gender, BMI (body mass index), and smoking status; Clinical parameters (Clin): eGFR, history of HF, and TIMI risk score; Biomarkers: NT-proBNP, hsTnT. In total, 4330 patients were included in the analysis and followed-up for an average of 1 year.

Descriptive statistics of GDF-15 (pg/mL) by subject baseline characteristics

	TIMI risk 0-2	TIMI risk 3-4	TIMI risk ≥ 5
N	1064	2323	943
Mean (pg/mL)	1119	1428	1926
SD (pg/mL)	906	1139	1409
Median (pg/mL)	922	1163	1522
5 th percentile (pg/mL)	471	551	677
95 th percentile (pg/mL)	2355	3181	4651

Relationship of log₂-transformed GDF-15 levels with all-cause mortality alone and with the addition of covariates

GDF-15 independently contributes to risk prediction of all-cause mortality in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	2.50 (2.21, 2.84)	< 0.0001	0.740 (0.706, 0.773)
GDF-15 + Dem	2.11 (1.82, 2.44)	< 0.0001	0.759 (0.727, 0.791)
GDF-15 + Dem + Clin	1.90 (1.61, 2.24)	< 0.0001	0.787 (0.757, 0.817)
GDF-15 + Dem + Clin + NT-proBNP	1.46 (1.22, 1.75)	< 0.0001	0.822 (0.794, 0.849)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.48 (1.23, 1.76)	< 0.0001	0.822 (0.795, 0.850)

Relationship of log₂-transformed GDF-15 levels with CV death alone and with the addition of covariates

GDF-15 independently contributes to risk prediction of CV death in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	2.46 (2.15, 2.81)	< 0.0001	0.733 (0.697, 0.769)
GDF-15 + Dem	2.07 (1.77, 2.42)	< 0.0001	0.758 (0.723, 0.792)
GDF-15 + Dem + Clin	1.78 (1.50, 2.13)	< 0.0001	0.796 (0.765, 0.827)
GDF-15 + Dem + Clin + NT-proBNP	1.37 (1.13, 1.67)	0.0012	0.827 (0.799, 0.855)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.39 (1.14, 1.68)	0.0009	0.829 (0.801, 0.857)

Relationship of log₂-transformed GDF-15 levels with composite CV death/MI alone and with the addition of covariates


GDF-15 independently contributes to risk prediction of composite CV death/MI in a Cox proportional hazard ratio (HR) adjusted for Dem, Clin and biomarkers:

Model	HR (95 % CI) of log ₂ -transformed GDF-15 levels	p-value	C-statistic 95 % CI
GDF-15 only	1.77 (1.60, 1.95)	< 0.0001	0.633 (0.606, 0.660)
GDF-15 + Dem	1.58 (1.41, 1.78)	< 0.0001	0.651 (0.625, 0.678)
GDF-15 + Dem + Clin	1.39 (1.23, 1.58)	< 0.0001	0.696 (0.671, 0.721)
GDF-15 + Dem + Clin + NT-proBNP	1.18 (1.04, 1.35)	0.0132	0.718 (0.693, 0.742)
GDF-15 + Dem + Clin + NT-proBNP + hsTnT	1.19 (1.04, 1.36)	0.0103	0.720 (0.696, 0.744)

These results demonstrate that GDF-15 provides significant independent prognostic information in patients with NSTEMI-ACS for an average of 1 year.

Similar models were created with categorized GDF-15 levels to define cutoffs separating patient groups with high, intermediate, and low risk for all-cause mortality and CV death as well as the composite of CV death/MI. Creating two binary GDF-15 factors using the rounded tertiles 1200 pg/mL and 1800 pg/mL as cutoffs, i.e. comparing low versus intermediate/high GDF-15 levels and low/intermediate versus high GDF-15 levels, in two separate models, resulted in HRs of 4.34 (≥ 1200 pg/mL) and 4.17 (≥ 1800 pg/mL) for **all-cause mortality**, for **CV death** HRs were 4.03 (≥ 1200 pg/mL) and 3.80 (≥ 1800 pg/mL) and for the composite of **CV death/MI** HRs were 2.16 (≥ 1200 pg/mL) and 2.13 (≥ 1800 pg/mL).

A similar model with a three category GDF-15 (low, intermediate and high) factor for **all-cause mortality** (see plot D below) resulted in HRs of 2.63 (intermediate vs. low) and 6.32 (high vs. low), for **CV death** (see plot E below) the HRs were 2.57 (intermediate vs. low) and 5.79 (high vs. low), and for the composite of **CV death/MI** (see plot F below) the HRs were 1.78 (intermediate vs. low) and 2.72 (high vs. low).



x = days
 y = (D) % free from all-cause mortality
 (E) % free from CV death
 (F) % free from CV death/MI

————: < 1200 pg/mL
 - - - : 1200-1799 pg/mL
 - · - · : ≥ 1800 pg/mL

GDF-15 derived risk stratification of patients with Atrial Fibrillation (AF)
 The novel ABC-bleeding risk score for prediction of major bleeding events using age, clinical history of bleeding, and the level of three biomarkers (GDF-15, cTNT-hs, and hemoglobin) was developed and validated in two large cohorts (ARISTOTLE²⁵ & RE-LY²⁶) of patients with AF treated with oral anticoagulation.¹³ The ABC-bleeding risk score demonstrated better discrimination and use than the widely used HAS-BLED and ORBIT score.

Derivation cohort

The ABC-bleeding risk score was developed from the ARISTOTLE trial cohort. ARISTOTLE was a double blind, randomized clinical trial that enrolled 18201 patients with AF at increased risk for stroke at 1034 clinical sites in 39 countries between December 2006 and April 2010. Due to the inclusion of 39 countries all major ethnicities (specifically ~25 % N. America, ~20 % Latin America, ~ 40 % Europe, ~16 % Asian) were represented and


characterized.

In the study the authors demonstrated that the strongest predictors were GDF-15, hemoglobin, cTNT-hs, age, and previous bleeding. Therefore, only these five variables were utilized in the final model due to the fact that they approximated 91.3 % of the full model. The score was given the acronym ABC-bleeding and demonstrated superiority over the HAS-BLED score (c-index 0.68 vs 0.61) and the ORBIT score (c-index 0.68 vs 0.65).^{13,25}

External validation cohort

The external validation was based on 16212 person-years of follow-up and 463 adjudicated major bleeding events in the RE-LY cohort. RE-LY was a prospective, multicenter, randomized trial comparing two blinded doses of dabigatran with open label warfarin that enrolled 18113 patients with AF at 951 clinical sites in 44 countries between December 2005 and March 2009. Due to the inclusion of 44 countries all major ethnicities were represented and characterized (specifically 15 % of patients from Asian countries). The analysis of the validation cohort confirmed the superiority of the ABC-bleeding risk score over the HAS-BLED score (c-index 0.71 vs 0.62) and the ORBIT score (c-index 0.71 vs 0.68).^{13,26}

The analysis of event rates within risk classes of both the derivation and validation data also showed that the ABC-bleeding risk score had good discriminative ability in different subgroups of patients with AF (see figure below).



1-year cumulative regression analysis of major bleeding for the derivation and the validation cohorts comprising the ABC-bleeding risk score.¹³

x = time (years)
 y = cumulative event rate

A-F = 1-year risk classes:

A = > 2 % (validation cohort); B = > 2 % (derivation cohort); C = 1-2 % (validation cohort); D = 1-2 % (derivation cohort); E = < 1 % (validation cohort); F = < 1 % (derivation cohort)

Specific performance data

Representative performance data on the analyzer is given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 801 analyzer					
		Repeatability		Intermediate precision	
Sample	Mean pg/mL	SD pg/mL	CV %	SD pg/mL	CV %
Human serum 1	472	6.13	1.3	7.65	1.6
Human serum 2	1175	13.5	1.1	23.2	2.0
Human serum 3	1777	16.7	0.9	22.1	1.2
Human serum 4	10296	99.1	1.0	147	1.4
Human serum 5	19368	213	1.1	295	1.5
PC ^{b)} Cardiac II 1	1402	10.5	0.7	16.3	1.2
PC Cardiac II 2	7307	69.1	0.9	88.1	1.2

b) PC = PreciControl

Method comparison

A comparison of the Elecsys GDF-15 assay, [REF] 07028172190 (cobas e 801 analyzer; y) with the Elecsys GDF-15 assay, [REF] 07125933190 (cobas e 601 analyzer; x) gave the following correlations (pg/mL):

Number of samples measured: 143

Passing/Bablok²⁷ Linear regression

$$y = 1.02x - 3.97 \quad y = 1.02x - 10.9$$

$$r = 0.989 \quad r = 1.00$$

The sample concentrations were between 403 and 18876 pg/mL.

Analytical specificity

No significant cross-reactivity was found for Tumor necrosis factor- β (< 0.2 %; tested concentration 100 ng/mL) and C-reactive protein (< 0.001 %; tested concentration 200 mg/L).

References

- Kempf T, Horn-Wichmann R, Brabant G et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. *Clin Chem* 2007;53(2):2284-291.
- Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. *Curr Heart Fail Rep* 2012;9:337-345.
- Kempf T, Björklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. *Eur Heart J* 2007;28:2858-2865.
- Wallentin L, Lindhagen L, Årnström E, et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. *Lancet* 2016;pii: S0140-6736(16)31276-4.
- Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. *Circulation* 2007;115:962-971.
- Wallentin L, Lindholm D, Siegbahn A, et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation* 2014;129:293-303.
- Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. *Circulation* 2010;122:1387-1395.
- Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. *J Am Coll Cardiol* 2007;50:1054-1060.

- Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. *Clin Chem* 2013;59:1497-1505.
- Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome. Observations from PROVE IT-TIMI 22. *Arterioscler Thromb Vasc Biol*. 2011;31(1):203-210.
- Pisters R, Lane DA, Nieuwlaar R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. *Chest* 2010;138:1093-100.
- O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. *Eur Heart J* 2015;36:3258-3264.
- Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet* 2016;387:2302-2311.
- Thomas J, Wang KC, Wollert MG, et al. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress The Framingham Heart Study. *Circulation* 2012;126:1596-1604.
- Xanthakis V, Enserro DM, Murabito JM, et al. Ideal Cardiovascular Health Associations With Biomarkers and Subclinical Disease and Impact on Incidence of Cardiovascular Disease in the Framingham Offspring Study. *Circulation* 2014;130:1676-1683.
- Gopal DM, Larson MG, Januzzi JL, et al. Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. *Clin Chem* 2014;60:1402-1408.
- Resl M, Clodi M, Vila G, et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. *Heart* 2016;102:1963-1968.
- Corre J, Hébraud B, Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role? *Stem Cells Trans Med* 2013;2:946-952.
- Pavo N, Wurm R, Neuhold S, et al. GDF-15 is associated with cancer incidence in patients with type 2 diabetes. *Clin Chem* 2016;62(12):1612-1620.
- Wallentin L, Zethelius B, Berglund L, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. *PLoS One* 2013;8(12):e78797.
- Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a biomarker in cardiovascular disease. *Clin Chem* 2017;63(1):140-151.
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *EHJ* 2016; Epub August 27.
- O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial. *JAMA* 2009;301(14):1439-1450.
- Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. For the MERLIN-TIMI 36 Trial Investigators, Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes The MERLIN-TIMI 36 Randomized Trial. *JAMA* 2007;297(16):1775-1783.
- Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. *Circulation* 2013;127(22):2166-2176.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361(12):1139-1151.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).







Elecsys GDF-15

cobas®

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2019, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

